Generic Name and Formulations:
Gadoversetamide 330.9mg/mL (0.5mmol/mL); soln for IV inj; preservative-free.
Liebel-Flarsheim Company LLC
Indications for OPTIMARK:
For use with MRI in patients with abnormal blood brain barrier or abnormal vascularity of the brain, spine and associated tissues. For use with MRI to provide contrast enhancement and facilitate visualization of lesions with abnormal vascularity in the liver of patients who are highly suspect for liver structural abnormalities on computed tomography.
Give as bolus peripheral IV inj at a rate of 1–2mL/sec, manually or by power injector. 0.2mL/kg (0.1mmol/kg), followed by 5mL normal saline flush to ensure complete injection.
Chronic, severe kidney disease (GFR <30mL/min/1.73m2). Acute kidney injury.
Nephrogenic systemic fibrosis (NSF).
Increased risk of nephrogenic systemic fibrosis in chronic kidney disease or acute kidney injury (see Contraindications). Screen for renal dysfunction. Do not exceed recommended dose and allow sufficient time for drug elimination before re-administration. Have emergency resuscitative equipment available. History of asthma or other allergic disorders. Monitor for signs/symptoms of hypersensitivity reactions during and for several hrs after administration; discontinue if occur. Increased risk of gadolinium retention with multiple lifetime doses, in pregnant patients, children, and those with inflammatory conditions; minimize repetitive imaging studies. Renal impairment: use lowest effective dose. Avoid extravasation. Interpreting Optimark MRI scans without a companion non-contrast MRI. Elderly. Pregnancy. Nursing mothers: not recommended (discard breast milk up to 72hrs after inj).
Gadolinium-based contrast agent.
Interference in serum iron, copper, zinc, and calcium measurements.
Headache, vasodilation, taste perversion, dizziness, nausea, paresthesia; hypersensitivity reactions.
Single-dose vials (5mL, 10mL, 15mL, 20mL)—10; Syringes (10mL, 15mL, 20mL, 30mL)—10